Mansoor A. Khan, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Mansoor A. Khan, PhD


Mansoor A. Khan, PhD
Director,
FDA/CDER/DPQR

Mansoor A. Khan is the director of product quality research in the Center for Drug Evaluation and Research at the US Food and Drug Administration. Prior to joining FDA, Khan was a professor of pharmaceutics and director of graduate program in the School of Pharmacy at Texas Tech University Health Sciences Center. He is a registered pharmacist, and earned his PhD in Industrial Pharmacy from the St. John's University School of Pharmacy at New York in 1992. He has published more than 135 peer-reviewed manuscripts, four texts including Pharmaceutical and Clinical Calculations, five book chapters, and given more than 125 presentations in various meetings. Khan advised 10 PhD students in pharmaceutics.

Khan's research focus is primarily in the area of quality by design and process analytical technologies, controlled drug delivery of challenging molecules, oral delivery of macromolecules, and nanoparticles. He is the chair-elect of Pharmaceutics and Drug Delivery section of the American Association of Pharmaceutical Scientists (AAPS), and has been recognized as an AAPS fellow. He serves on the editorial board of Pharmaceutical Technology, the Journal of Clinical Research and Regulatory Affairs, and the journal Critical Reviews in Therapeutic Drug Carrier Systems.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here